A systematic review of the HPV-attributable fraction of oropharyngeal squamous cell carcinomas in Germany.


Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
04 2019
Historique:
received: 02 11 2018
revised: 09 01 2019
accepted: 29 01 2019
pubmed: 2 3 2019
medline: 12 5 2020
entrez: 2 3 2019
Statut: ppublish

Résumé

The prevalence of oropharyngeal squamous cell carcinoma (OPSCC) is increasing globally while the prevalence of other head and neck cancers is decreasing. The most likely reasons for this are a decreasing influence of smoking and the growing relevance of infections with the human papilloma virus (HPV) as a risk factor. A rise in the HPV-attributable fraction (HPV-AF) of OPSCC has been observed in many countries, yet a comprehensive review of prevalence rates and trends in Germany is lacking. To determine the current HPV-AF of OPSCC in Germany and to assess whether it has changed during the last decades, we performed a systematic literature review. We screened Medline and EMBASE for studies that reported the tumor HPV status of newly diagnosed OPSCC patients treated at medical centers in Germany by testing for both HPV DNA and p16

Identifiants

pubmed: 30821126
doi: 10.1002/cam4.2039
pmc: PMC6488137
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1908-1918

Informations de copyright

© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Références

Cancer Med. 2019 Apr;8(4):1908-1918
pubmed: 30821126
Int J Cancer. 2006 Dec 1;119(11):2620-3
pubmed: 16991119
Cancer J. 2015 May-Jun;21(3):138-46
pubmed: 26049691
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Virchows Arch. 2015 Jun;466(6):685-93
pubmed: 25820374
PLoS One. 2014 Jan 24;9(1):e86023
pubmed: 24475067
Dtsch Arztebl Int. 2013 Mar;110(11):184-90, 190e1
pubmed: 23555322
J Natl Cancer Inst. 2015 Dec 09;107(12):djv344
pubmed: 26656751
JAMA. 2014 Jan 8;311(2):183-92
pubmed: 24399557
Cancer. 2007 Oct 1;110(7):1429-35
pubmed: 17724670
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Int J Cancer. 2007 Apr 15;120(8):1731-8
pubmed: 17236202
Int J Cancer. 2011 Aug 1;129(3):733-41
pubmed: 20878955
Int J Cancer. 2013 Apr 1;132(7):1565-71
pubmed: 22949073
Int J Cancer. 2010 Oct 1;127(7):1595-602
pubmed: 20091864
Vaccine. 2010 Apr 26;28(19):3269-72
pubmed: 20226244
Dtsch Arztebl Int. 2017 Aug 21;114(33-34):545-550
pubmed: 28855044
Semin Oncol. 2004 Dec;31(6):744-54
pubmed: 15599852
N Engl J Med. 2007 May 10;356(19):1944-56
pubmed: 17494927
Eur J Cancer. 2015 Mar;51(4):514-21
pubmed: 25623438
Int J Cancer. 2014 Mar 15;134(6):1323-34
pubmed: 23996702
J Natl Cancer Inst. 2016 Jan 28;108(6):djv403
pubmed: 26823521
J Natl Cancer Inst. 2003 Dec 3;95(23):1772-83
pubmed: 14652239
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Int J Cancer. 2007 Jun 1;120(11):2386-92
pubmed: 17315185
HNO. 2013 Jul;61(7):593-601
pubmed: 23842698
BMC Cancer. 2017 Oct 16;17(1):682
pubmed: 29037233
Cell Oncol (Dordr). 2013 Jun;36(3):213-24
pubmed: 23529585
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Cancer Res. 2012 Oct 1;72(19):4993-5003
pubmed: 22991302
Cancer Lett. 2018 Jan 28;413:59-68
pubmed: 29100961
Lancet Oncol. 2010 Aug;11(8):781-9
pubmed: 20451455
PLoS One. 2014 Dec 02;9(12):e114170
pubmed: 25463965
Oral Oncol. 2006 Jul;42(6):586-92
pubmed: 16469526
BMC Cancer. 2014 Mar 14;14:187
pubmed: 24629046
Int J Cancer. 2017 Mar 1;140(5):1186-1198
pubmed: 27859245
J Natl Cancer Inst. 1998 Nov 4;90(21):1626-36
pubmed: 9811312
Community Dent Oral Epidemiol. 2017 Feb;45(1):20-34
pubmed: 27642003
J Clin Oncol. 2013 Dec 20;31(36):4550-9
pubmed: 24248688
Ann Oncol. 2017 Oct 1;28(10):2386-2398
pubmed: 28633362
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Cancer. 1998 Apr 1;82(7):1367-75
pubmed: 9529030
Cancer Res. 1988 Jun 1;48(11):3282-7
pubmed: 3365707
Cancer Lett. 2012 Oct 1;323(1):88-96
pubmed: 22484467
Front Oncol. 2017 Jun 30;7:129
pubmed: 28713770
Anticancer Res. 2013 Aug;33(8):3481-5
pubmed: 23898123
Head Neck. 2015 Nov;37(11):1618-24
pubmed: 24955923
Lancet Oncol. 2014 Nov;15(12):1319-31
pubmed: 25439690

Auteurs

Miriam Reuschenbach (M)

Department of Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany.

Ingeborg Tinhofer (I)

German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany.
Department of Radiation Oncology and Radiotherapy, Charité University Medicine Berlin, Berlin, Germany.

Claus Wittekindt (C)

Department of Otorhinolaryngology, Head and Neck Surgery, University of Giessen, Giessen, Germany.

Steffen Wagner (S)

Department of Otorhinolaryngology, Head and Neck Surgery, University of Giessen, Giessen, Germany.

Jens Peter Klussmann (JP)

Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH